(WFRF:(Mulder H))
Search: (WFRF:(Mulder H)) > (2005-2009) > 6-thioguanine treat...
- 5 of 11
- Previous record
- Next record
- To hitlist
6-thioguanine treatment in inflammatory bowel disease : A critical appraisal by a European 6-TG working party
- de Boer, NKH (author)
- Reinisch, W (author)
- Teml, A (author)
- show more...
- van Bodegraven, AA (author)
- Schwab, M (author)
- Lukas, M (author)
- Ochsenkuhn, T (author)
- Petritsch, W (author)
- Knoflach, P (author)
- van der Merwe, SW (author)
- Herrlinger, KR (author)
- Seiderer, J (author)
- Vogelsang, H (author)
- Mulder, CJJ (author)
- show less...
- (creator_code:org_t)
- 2009-01-28
- 2006
- English.
- In: Digestion. - : S. Karger AG. - 0012-2823 .- 1421-9867. ; 73:1, s. 25-31
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004, European experts applying 6-TG further on in IBD patients presented data on safety and efficacy of 6-TG. After thorough evaluation of its risk-benefit ratio, the group consented that 6-TG may still be considered as a rescue drug in stringently defined indications in IBD, albeit restricted to a clinical research setting. As a potential indication for administering 6-TG, we delineated the requirement for maintenance therapy as well as intolerance and/or resistance to aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate and infliximab. Furthermore, indications are preferred in which surgery is thought to be inappropriate. The standard 6-TG dosage should not exceed 25 mg daily. Routine laboratory controls are mandatory in short intervals. Liver biopsies should be performed after 6-12 months, three years and then three-yearly accompanied by gastroduodenoscopy, to monitor for potential hepatotoxicity, including nodular regenerative hyperplasia (NRH) and veno-occlusive disease (VOD). Treatment with 6-TG must be discontinued in case of overt or histologically proven hepatotoxicity. Copyright (c) 2006 S. Karger AG, Basel.
Keyword
- 6-thioguanine
- thiopurine
- inflammatory bowel disease
- Crohn's disease and ulcerative colitis
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
- 5 of 11
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- de Boer, NKH
- Reinisch, W
- Teml, A
- van Bodegraven, ...
- Schwab, M
- Lukas, M
- show more...
- Ochsenkuhn, T
- Petritsch, W
- Knoflach, P
- Almer, Sven
- van der Merwe, S ...
- Herrlinger, KR
- Seiderer, J
- Vogelsang, H
- Mulder, CJJ
- show less...
- Articles in the publication
- Digestion
- By the university
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
